SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (1459)12/4/2007 12:52:08 PM
From: keokalani'nui  Read Replies (2) | Respond to of 1494
 
ntii guided in last call they were looking to in-license a cpd (I paraphrase) 'responding to shareholders' concerns that they were a one drug company.'

Left field, yes. Company warned they we going out into left field to facilitate a left field event.

Management just taking its fiduciary duties seriously.

I bet recent investors hang around no longer than 8 months.



To: rkrw who wrote (1459)12/4/2007 1:23:36 PM
From: JMarcus  Respond to of 1494
 
If clinical trials for the Buck compound are going to take a while, then the additional near-term burn should be modest. Sounds like NTII is positioning itself for where it can, a little later, spend the profits it will be making from sales of Viprinex once it receives FDA approval. I can see the sense in doing that.

Marc


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News